Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial.
| Publicado en: | Journal of Clinical Oncology Vol. 42; pp. 139 - 159 |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
American Society of Clinical Oncology
2024 Supplement
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178967434&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 178967434 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0732183X 20D jtl: Journal of Clinical Oncology issn: 0732183X maglogo: N pubinfo: dt: 2024 Supplement vid: 42 pid: 26892 pub: American Society of Clinical Oncology place: Alexandria, Virginia artinfo: ui: 178967434 10.1200/JCO.2024.42.23_suppl.139 178967434 ppf: 139 ppct: 20 formats: tig: atl: Safety, tolerability, and immunogenicity of WGc-043 in subjects with EBV-positive cancers: Results from an investigator-initiated trial. aug: au: Peng, Xingchen He, Xuan Zhang, Weiwei Huang, Hai Li, Xue Chen, Jie Wei, Yuquan Song, Xiangrong affil: West China Hospital, Sichuan University, Chengdu, China sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|